ArticleHistopathology2020
Pulmonary pathology of early-phase COVID-19 pneumonia in a patient with a benign lung lesion.
Article in Histopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Pooled it
- A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Pooled it
- Evaluation of artificial intelligence identified ipratropium bromide for the treatment of coronavirus disease 2019.Scientific reports · 2026Article
- Mapping cellular signaling pathways involved in SARS-CoV-2 spike protein-mediated syncytia formation.Infectious diseases & immunity · 2026Article
- Autoimmune reactions to ACE2 triggered by SARS-CoV-2 S protein and their histopathological consequences.Scientific reports · 2025Article
- Histopathological examination of lung from infant with lethal COVID-19 with special attention on pneumocytes type II and the immune infiltrate: a case study.Italian journal of pediatrics · 2025Article
- Interstitial macrophages are a focus of viral takeover and inflammation in COVID-19 initiation in human lung.The Journal of experimental medicine · 2024Article
- Immunomodulatory effect of bovine lactoferrin during SARS-CoV-2 infection.Frontiers in immunology · 2024Article
- Histologic Characteristics and Clinical Courses of Primary Viral Pneumonia Other than COVID-19.Internal medicine (Tokyo, Japan) · 2023Article
- COVID-19 and lung cancer.Pathologica · 2023Review
- SARS-CoV-2 cellular tropism and direct multiorgan failure in COVID-19 patients: Bioinformatic predictions, experimental observations, and open questions.Cell biology international · 2023Review
- Post COVID-19 pulmonary mass: Case report and review of literatures.Saudi medical journal · 2022Review
- The mechanistic basis linking cytokine storm to thrombosis in COVID-19.Thrombosis update · 2022Review
- Bronchial epithelia from adults and children: SARS-CoV-2 spread via syncytia formation and type III interferon infectivity restriction.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Highly Prevalent SARS-CoV-2 Antigenemia in COVID-19 Patients.Infectious diseases & immunity · 2022Article
- Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020.Cancer immunology, immunotherapy : CII · 2022Article
- Positive airway pressure longer than 24 h is associated with histopathological volutrauma in severe COVID-19 pneumonia-an ESGFOR based narrative case-control review.Annals of translational medicine · 2022Review
- Lung Aeration in COVID-19 Pneumonia by Ultrasonography and Computed Tomography.Journal of clinical medicine · 2022Article
- Multiscale Model of Antiviral Timing, Potency, and Heterogeneity Effects on an Epithelial Tissue Patch Infected by SARS-CoV-2.Viruses · 2022Article
- Outcome predictors in COVID-19: An analysis of emergent systemic inflammation indices in Mexican population.Frontiers in medicine · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
aimsAn ongoing outbreak of 2019 novel coronavirus (CoV) disease (COVID-19), caused by severe acute respiratory syndrome (SARS) CoV-2, has been spreading in multiple countries. One of the reasons for the rapid spread is that the virus can be transmitted from infected individuals without symptoms. Revealing the pathological features of early-phase COVID-19 pneumonia is important for understanding of its pathogenesis. The aim of this study was to explore the pulmonary pathology of early-phase COVID-19 pneumonia in a patient with a benign lung lesion. METHODS AND
resultsWe analysed the pathological changes in lung tissue from a 55-year-old female patient with early-phase SARS-CoV-2 infection. In this case, right lower lobectomy was performed for a benign pulmonary nodule. Detailed clinical, laboratory and radiological data were also examined. This patient was confirmed to have preoperative SARS-CoV-2 infection by the use of real-time reverse transcription polymerase chain reaction and RNA in-situ hybridisation on surgically removed lung tissues. Histologically, COVID-19 pneumonia was characterised by exudative inflammation. The closer to the visceral pleura, the more severe the exudation of monocytes and lymphocytes. Perivascular inflammatory infiltration, intra-alveolar multinucleated giant cells, pneumocyte hyperplasia and intracytoplasmic viral-like inclusion bodies were seen. However, fibrinous exudate and hyaline membrane formation, which were typical pulmonary features of SARS pneumonia, were not evident in this case. Immunohistochemical staining results showed an abnormal accumulation of CD4+ helper T lymphocytes and CD163+ M2 macrophages in the lung tissue.
conclusionThe results highlighted the pulmonary pathological changes of early-phase SARS-CoV-2 infection, and suggested a role of immune dysfunction in the pathogenesis of COVID-19 pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.